Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.44 |
| ▸ | MAPT | P10636 | 2/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.38 |
| ▸ | MAOA | P21397 | 2/20 | 0.37 |
| ▸ | MAOB | P27338 | 2/20 | 0.37 |
| ▸ | TRPV4 | Q9HBA0 | 1/20 | 0.37 |
| ▸ | LGALS8 | O00214 | 2/20 | 0.36 |
| ▸ | PGR | P06401 | 1/20 | 0.36 |
| ▸ | LGALS1 | P09382 | 1/20 | 0.36 |
| ▸ | LGALS3 | P17931 | 1/20 | 0.36 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.36 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4879959 | 0.76 | KDM4E (0.59) | KDM4EMAPTTDP1HPGDHSD11B1 | |
| SCHEMBL4882690 | 0.75 | BRPF1 (0.45) | KDM4EMAPTHSD11B1TRPV4PGR | |
| SCHEMBL4879097 | 0.74 | ITGA1 (0.51) | MAPTMAOAMAOBLMNA | |
| SCHEMBL4175248 | 0.73 | KDM4E (0.56) | KDM4EMAPTHSD11B1TRPV4PGR | |
| SCHEMBL713590 | 0.73 | KDM4E (0.44) | KDM4EHSD11B1MAOBTRPV4PGR | |
| SCHEMBL716311 | 0.73 | KDM4E (0.44) | KDM4EMAPTHSD11B1TRPV4PGR | |
| SCHEMBL266816 | 0.72 | CYP2A6 (0.59) | KDM4EMAPTCYP1A2GAAHPGD | |
| SCHEMBL14018589 | 0.72 | SMN1; SMN2 (0.48) | KDM4EMAPTGAAHSD11B1TRPV4 | |
| SCHEMBL8279477 | 0.71 | MAPT (0.46) | KDM4EMAPTTDP1HPGDMAOA | |
| SCHEMBL714422 | 0.71 | MAPT (0.46) | KDM4EMAPTTDP1HPGDMAOA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080255169-A1 | 4'-Fluoro-biphenyl-3-sulfonic acid benzo[1,3]dioxol-5-ylamide, for example; for use as an alpha 2 beta 1 integrin I domain inhibitor; use as a medicament for treating thrombosis and cancer spread | BIOTIE THERAPIES CORPORATION (FI) | 2008-10-16 | — | — | US | disclosed |
| US-20080255169-A1 | 4'-Fluoro-biphenyl-3-sulfonic acid benzo[1,3]dioxol-5-ylamide, for example; for use as an alpha 2 beta 1 integrin I domain inhibitor; use as a medicament for treating thrombosis and cancer spread | BIOTIE THERAPIES CORPORATION (FI) | 2008-10-16 | — | — | US | disclosed |
| US-20080255169-A1 | 4'-Fluoro-biphenyl-3-sulfonic acid benzo[1,3]dioxol-5-ylamide, for example; for use as an alpha 2 beta 1 integrin I domain inhibitor; use as a medicament for treating thrombosis and cancer spread | BIOTIE THERAPIES CORPORATION (FI) | 2008-10-16 | — | — | US | disclosed |
| EP-1732884-A1 | SULPHONAMIDE DERIVATIVES | Biotie Therapies Corp. (FI) | 2006-12-20 | — | — | EP | disclosed |
| WO-2005090298-A1 | SULPHONAMIDE DERIVATIVES | BIOTIE THERAPIES CORPORATION (FI) | 2005-09-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080255169-A1 | 4'-Fluoro-biphenyl-3-sulfonic acid benzo[1,3]dioxol-5-ylamide, for example; for use as an alpha 2 beta 1 integrin I domain inhibitor; use as a medicament for treating thrombosis and cancer spread | NR1I2, ITGA2, ITGB2 | KDM4E 1548/4885MAPT 4739/4885TDP1 4009/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.